Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma

被引:0
作者
Jing Liao
Dan-Ni Zeng
Jin-Zhu Li
Qiao-Min Hua
Zhiyu Xiao
Chuanchao He
Kai Mao
Ling-Yan Zhu
Yifan Chu
Wei-Ping Wen
Limin Zheng
Yan Wu
机构
[1] Sun Yat-sen University,MOE Key Laboratory of Gene Function and Regulation, School of Life Sciences
[2] Sun Yat-sen University,Guangdong Institute of Gastroenterology, The Sixth Affiliated Hospital
[3] Sun Yat-sen University,Department of Hepatobiliary Surgery, Sun Yat
来源
Hepatology International | 2020年 / 14卷
关键词
Hepatocellular carcinoma; Sorafenib; T cells exhaustion; Adenosinergic pathway; Immunotherapy;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:80 / 95
页数:15
相关论文
共 229 条
[1]  
Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424
[2]  
Ferlay J(2019)The hepatocellular carcinoma market Nat Rev Drug Discov 18 13-14
[3]  
Soerjomataram I(2014)The role of inflammation and liver cancer Adv Exp Med Biol 816 401-435
[4]  
Siegel RL(2019)Immunotherapy in hepatocellular carcinoma Ann Hepatol 18 291-297
[5]  
Torre LA(2013)Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma Nat Rev Cancer 13 123-135
[6]  
Jemal A(2016)Hepatocellular carcinoma Nat Rev Dis Primers 2 16018-943
[7]  
Dawkins J(2012)EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma J Hepatol 56 908-331
[8]  
Webster RM(2014)Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity Int J Cancer 134 319-390
[9]  
Bishayee A(2008)Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378-1022
[10]  
Buonaguro L(2013)Innate and adaptive immune cells in the tumor microenvironment Nat Immunol 14 1014-960